Tempus’ Patient-Derived Organoid (PDO) Screens

Evaluate the efficacy of your preclinical drug candidates across a range of therapeutic modalities—including small molecules, monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), cell therapies, and bispecific T-cell engagers. 

Key insights:

• Viability assessments, including IC50 and EC50 analyses, via luminescence and/or fluorescence readouts
• Responses to indication- or biomarker-specific standard-of-care (SOC) therapies
• Molecular profiling, including Differential Gene Expression (DGE) and Gene Set Enrichment Analysis (GSEA), to identify molecular drivers of response or resistance

Complete the form to enroll now.

Interested in integrating PDO screen findings with real-world data (RWD)? Learn more about Tempus Loop—our proprietary platform that connects RWD, PDOs, and AI/ML to help rapidly identify and validate actionable targets in oncology R&D.